Pfizer, COVID-19
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal.
Updated Pfizer-BioNTech’s COVID-19 vaccine approved by Health Canada
Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and
Pfizer and BioNTech’s Omicron KP.2-Adapted COVID-19 Vaccine Receives Positive EU Opinion, Awaiting Approval
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA)
Pfizer's updated COVID-19 vaccine approved, Health Canada says
Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.
Health Canada approves Pfizer-BioNTech's updated COVID-19 vaccine
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.
Pfizer/BioNTech Covid-19 Vaccine Adapted for KP.2 Strain Gets Canada Approval
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
STAT21h
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer and its partner, BioNTech, sued Moderna in London in September 2022, seeking to revoke two patents held by Moderna ...
WETM-TV3h
Judge dismisses family lawsuit against Dept. of Defense after 24-year-old’s “vaccine-related” death
A federal judge in Washington D.C. cited the government’s “general immunity” in dismissing a lawsuit that accused the ...
Study confirms effectiveness of the new omicron booster
The autumn wave of coronavirus is sweeping across Germany. Those affected mainly suffer from coughs, colds, sore throats and ...
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...
Business Insider18h
Pfizer’s Hold Rating: Evaluating the Impact of Oxbryta Withdrawal and Pipeline Uncertainties
While Pfizer is developing a next-generation version of Oxbryta ... Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Eli Lilly & Co, and Regeneron. In another report ...
Pfizer’s updated COVID-19 vaccine approved by Health Canada
The mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the ...
Pfizer withdraws sickle cell drug Oxbryta over safety concerns
Pfizer (PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety ...
Pfizer’s Solid Fundamentals and Strategic Acquisitions Affirm Buy Rating Despite Oxbryta Setback
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report), retaining the price target of $36.00.